An observational study in Obesity and Myopia, sponsored by Southeast University, China. Recruiting at 1 site in China. Open to participants aged 6 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Southeast University, China · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 603 studies in Obesity with a site in China — 223 open to participants now, 284 under way, 67 of them phase 3. Obesity · China.
Among the 603 studies in Obesity with a site in China, this one is the 44th largest by planned enrollment of the 99 observational ones that give a count, is one of 115 that started in 2025, is one of 99 observational ones, reaches primary completion later than 180 of the 282 other live ones, and was the 602nd registered.
11,564 studies on the registry are indexed under Obesity; 2,059 are open to participants now.
Browse Obesity studies →223 of the 603 studies in Obesity with a site in China are open now. Recruiting first, the newest first:
Chendu DIAO Pharmaceutical Group CO., LTD. · Sites in China
Ages 18–65
The First Hospital of Jilin University · Sites in China
Ages 18–65
Pfizer · Sites in China
Ages 18+
Eli Lilly and Company · Sites in China, United States, Argentina and 8 more countries
Ages 18+
The United Bio-Technology (Hengqin) Co., Ltd. · Sites in China
Ages 18–55
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 1,350 Obesity studies recruiting now, 382 (28%) set no upper age limit and 864 (64%) stop at 75 or younger; 168 take children under 18; 490 take healthy volunteers.
This study: 6 Years to 18 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
603 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 103 · Phase 2 70 · Phase 3 108 · Phase 4 28
First in 1997; this study’s year is marked. 115 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 600 is above the median of 115 across 2,158 observational studies indexed under Obesity.
Median enrollment 120 across the 504 interventional studies, 320 across the 99 observational. Of the 242 that completed or were terminated, 13 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
241 of 603 have an industry lead sponsor. The 10 most frequent:
Southeast University, China is the lead sponsor of 169 studies on the registry; 46 are open to participants now.
Southeast University, China has 1 study filed under Obesity — fewer than ten, so there is no comparison to draw.
106 of the studies in Obesity with a site in China that are under way reach primary completion within a year, 20 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06974851Phase 3Fujian Shengdi Pharmaceutical Co., Ltd.A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity | 2026-12 |
| NCT06994650Phase 3Fujian Shengdi Pharmaceutical Co., Ltd.A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Ventilation (PAP) Therapy | 2026-12 |
| NCT06672549Phase 3Eli Lilly and CompanyA Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) | 2027-02 |
| NCT07481747Phase 3Hudson BiotechEfficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1) | 2027-02-14 |
| NCT07285902Phase 3Fujian Shengdi Pharmaceutical Co., Ltd.A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity | 2027-03 |
Add all 106 to your calendar (.ics) → With an account.
Among the 603 studies in Obesity with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective observational cohort study will examine the association between obesity and myopia in children and adolescents. Approximately 600 participants aged 6 to 18 years will be enrolled at the Fourth Affiliated Hospital of Nanjing Medical University, including 300 participants with obesity and 300 participants with a body mass index within the normal range.
Participants will not be assigned to any study intervention. The study will collect information from body measurements, body composition assessments, eye examinations, lifestyle questionnaires, follow-up assessments, and existing clinical records. The investigators will evaluate whether obesity-related measures, including body mass index, body mass index z-score, body fat percentage, and visceral fat, are associated with myopia, axial length, refractive status, and changes in these outcomes over time. Lifestyle factors such as outdoor activity, near work, screen use, sleep, and diet will also be considered.
This is a single-center, prospective, observational cohort study involving children and adolescents aged 6 to 18 years who attend the pediatric outpatient clinic of the Fourth Affiliated Hospital of Nanjing Medical University. Approximately 600 participants will be enrolled, including 300 participants with obesity and 300 participants with a body mass index within the normal range. Obesity will be defined according to the Chinese screening standard for overweight and obesity among school-aged children and adolescents (WS/T 586-2018).
No randomization, masking, or study-related clinical intervention will be performed. At baseline, the study will collect anthropometric measurements, body composition data, ophthalmic examination results, and lifestyle questionnaire data. Planned follow-up assessments will be used to evaluate changes in refractive status, axial length, scleral thickness, and myopia progression.
The principal study outcomes include myopia status and changes in axial length, spherical equivalent refraction, scleral thickness, and myopia progression. The study will examine associations between these outcomes and obesity-related measures, including body mass index, body mass index z-score, body fat percentage, and visceral fat.
Information on age, sex, parental history of myopia, birth history, medical history, medication use, outdoor activity, near work, screen use, sleep, and diet will be collected as potential confounding factors. Existing clinical laboratory results obtained during routine medical care, including blood lipids, fasting blood glucose, fasting insulin, C-peptide, and glycated hemoglobin, may be included in exploratory analyses when available.
The study will not collect additional blood, stool, or other biological samples solely for research purposes and will not increase the frequency or volume of blood collection. If residual blood remaining after routine clinical testing is available and its use is permitted by the ethics approval and informed consent, it may be used for related laboratory measurements without additional blood collection. The absence of existing laboratory results or residual blood will not affect study eligibility.
Statistical analyses will include group comparisons, multivariable linear or logistic regression, and linear mixed-effects models for repeated follow-up measurements. Analyses will adjust for relevant demographic, familial, and lifestyle factors.
The study population will consist of approximately 600 children and adolescents aged 6 to 18 years attending the pediatric outpatient clinic of the Fourth Affiliated Hospital of Nanjing Medical University. Potential participants will be identified through the pediatric outpatient system and referrals from outpatient physicians. Approximately 300 participants will be enrolled in the obesity cohort and 300 in the normal-BMI cohort according to WS/T 586-2018. Enrollment requires written informed consent from a legal guardian and assent from the child or adolescent, as applicable.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Approximately 300 children and adolescents aged 6 to 18 years whose body mass index meets the definition of obesity in the Chinese screening standard for overweight and obesity among school-aged children and adolescents (WS/T 586-2018). Participants will undergo observational assessments only and will not be assigned to a study intervention.
Other: Health Education
Approximately 300 children and adolescents aged 6 to 18 years whose body mass index is within the normal range according to the Chinese screening standard for overweight and obesity among school-aged children and adolescents (WS/T 586-2018). Participants will undergo observational assessments only and will not be assigned to a study intervention.
The program should emphasize the health consequences of obesity and evidence-based weight management strategies, including maintaining a balanced diet, controlling energy intake, increasing physical activity, reducing sedentary behavior and screen time, and ensuring adequate sleep. Instruction, individualized counseling, and family involvement should be incorporated to improve health awareness and self-management skills and facilitate the development of a healthy lifestyle.
Change From Baseline in Axial Length
Axial length will be measured in millimeters for each eye using the same non-contact optical biometer at baseline and follow-up. Change in axial length (ΔAL) will be calculated as the value at 24 months minus the baseline value. Positive values indicate axial elongation. Changes will be compared between children and adolescents with obesity and those with normal weight. Associations of BMI, BMI-for-age Z score, body fat percentage, and visceral fat level with ΔAL will also be evaluated.
Time frame: Baseline and 24 months
Change From Baseline in Spherical Equivalent Refractive Error
Spherical equivalent refractive error will be calculated for each eye as spherical power plus one-half of cylindrical power and expressed in diopters (D), based on cycloplegic autorefraction. Change in spherical equivalent refractive error (ΔSE) will be calculated as the value at 24 months minus the baseline value. A negative change indicates a myopic shift. Changes will be compared between children and adolescents with obesity and those with normal weight. Associations of BMI, BMI-for-age Z score, body fat percentage, and visceral fat level with ΔSE will also be evaluated.
Time frame: Baseline and 24 months
Change From Baseline in Scleral Thickness
Scleral thickness will be measured in micrometers at the same predefined anatomical location using optical coherence tomography at baseline and follow-up. Change in scleral thickness (ΔST) will be calculated as the value at 24 months minus the baseline value. A negative change indicates scleral thinning. Changes will be compared between children and adolescents with obesity and those with normal weight.
Time frame: Baseline and 24 months
Change From Baseline in Regional Choroidal Thickness at 24 Months
Intraocular pressure, corneal curvature radius, mean keratometry, central corneal thickness, and anterior chamber depth will be measured in both eyes using the same standardized ophthalmic instruments at baseline and at the 24-month follow-up. Changes will be calculated as the 24-month value minus the corresponding baseline value. Intraocular pressure will be expressed in mmHg, corneal curvature radius and anterior chamber depth in millimeters, mean keratometry in diopters, and central corneal thickness in micrometers. Each parameter will be analyzed and reported separately.
Time frame: Baseline and 24 months
Change From Baseline in Regional Retinal Thickness at 24 Months
Retinal thickness will be measured in micrometers at predefined temporal, central foveal, and nasal locations in both eyes using optical coherence tomography. Change at each location will be calculated as the value at 24 months minus the corresponding baseline value. Measurements from the temporal, central foveal, and nasal locations will be analyzed and reported separately.
Time frame: Baseline and 24 months
Change From Baseline in Fasting Lipid Profile at 24 Months
Fasting lipid profile will include total cholesterol, triglycerides, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol, all expressed in mmol/L. Laboratory results obtained during routine clinical care will be collected at baseline and at 24 months when available. Change in each lipid parameter will be calculated as the 24-month value minus the corresponding baseline value. Each lipid parameter will be analyzed and reported separately. No additional blood sampling will be performed solely for this study.
Time frame: Baseline and 24 months
Body Fat Percentage
Body fat percentage will be estimated using bioelectrical impedance analysis and expressed as a percentage of total body mass.
Time frame: Baseline and 24 months
Body Fat Mass
Fat mass will be estimated using bioelectrical impedance analysis and expressed in kilograms (kg).
Time frame: Baseline and 24 months
Body Muscle Mass
Muscle mass will be estimated using bioelectrical impedance analysis and expressed in kilograms (kg).
Time frame: Baseline and 24 months
Total Body Water
Total body water will be estimated using bioelectrical impedance analysis and expressed in liters (L).
Time frame: Baseline and 24 months
Change From Baseline in Fasting Plasma Glucose at 24 Months
Change in fasting plasma glucose will be calculated as the 24-month value minus the baseline value and expressed in mmol/L.
Time frame: Baseline and 24 months
Change From Baseline in Fasting Insulin at 24 Months
Change in fasting insulin will be calculated as the 24-month value minus the baseline value and expressed in µIU/mL.
Time frame: Baseline and 24 months
Change From Baseline in C-Peptide at 24 Months
Change in C-peptide concentration will be calculated as the 24-month value minus the baseline value and expressed in pmol/L.
Time frame: Baseline and 24 months
Change From Baseline in Hemoglobin A1c (HbA1c) at 24 Months
Change in hemoglobin A1c (HbA1c) will be calculated by subtracting the baseline HbA1c percentage from the 24-month HbA1c percentage. The change will be expressed in percentage points.
Time frame: Baseline and 24 months
Change From Baseline in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) at 24 Months
At each visit, HOMA-IR will be calculated as fasting plasma glucose (mmol/L) multiplied by fasting insulin (µIU/mL), divided by 22.5, when both measurements are available from the same visit. Change will be calculated as the 24-month HOMA-IR value minus the baseline HOMA-IR value. HOMA-IR is a unitless index.
Time frame: Baseline and 24 months
Plan to share: No
Started Jul 2025 (actual). Primary completion is estimated for Jul 2027, 24 months after the start.
Of 795 non-industry observational studies under Obesity, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 106. This study's planned 24 months is below that.
Counting every sponsor, half of 841 studies reached it within 39 months; a quarter within 17 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.